# CRISPR and CAR-T, NK Current application and future perspective

mohadeseh khoshandam[1], Mohadeseh Khoshandam[2,3], Hossein Soltaninejad[4,5], Amir Ali Hamidieh[5], and Saman Hosseinkhani[6]

[1]Affiliation not available
[2]Department of Reproductive Biology, Academic Center for Education, Culture, and Research (ACECR)
[3]National institute of genetic engineering and biotechnology (NIGEB)
[4]Faculty of Interdisciplinary Science and Technology, Tarbiat Modares University
[5]Pediatric Cell Therapy and Gene Therapy Research Center, Gene ,Cell & Tissue Research Institute, Tehran University of Medical Sciences
[6]Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University

June 21, 2022

# CRISPR and CAR-T, NK Current application and future perspective

**Mohadeseh Khoshandam[1,2], Hossein Soltaninejad[3,4] , Amir Ali Hamidieh[4], Saman Hosseinkhani[5]**

**1-Department of Reproductive Biology, Academic Center for Education, Culture, and Research (ACECR), Qom branch, Iran.**

**2- National institute of genetic engineering and biotechnology (NIGEB), Tehran, Iran**

**3-Faculty of Interdisciplinary Science and Technology, Tarbiat Modares University, Tehran, Iran**

**4- Pediatric Cell Therapy and Gene Therapy Research Center ,Gene ,Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran**

**5- Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University,Tehran, Iran**

**Abstract**

Chimeric Antigen Receptor T-cells represent a breakthrough in personalized cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition, signaling, and stimulatory domains are used to reprogram T-cells to target tumor cells for destruction. Despite the success of this approach in refractory B-cell malignancies, optimal potency of CAR T-cell therapy for many other cancers, particularly solid tumors, has not been achieved. NK cells are powerful cytotoxic lymphocytes specialized in recognizing and dispensing with changed cells, and in coordinating versatile anti-tumor immunity.NK cells are as a rule practically depleted within the tumor microenvironment. In like manner, current investigate endeavors center on exactness designing of CAR T-cells with routine CRISPR-Cas9 frameworks or novel editors that can introduce craved hereditary changes with or without presentation of a double-stranded break into the genome. These instruments and methodologies can be specifically connected to focusing on negative controllers of T-cell work, coordinating helpful transgenes to particular genomic loci, and producing reproducibly secure and powerful allogeneic widespread CAR T-cell items for on-demand cancer immunotherapy. The revelation and improvement of the CRISPR/Cas9 innovation offer an adaptable and proficient gene-editing capability in tweaking different pathways that intercede NK cell fatigue and in outfitting NK cells with novel chimeric antigen receptors to particularly target tumor cells. Despite the tall productivity in its gene-editing capability, trouble within the conveyance of the CRISPR/Cas9 framework remains a major bottleneck for its restorative applications, especially for NK cells.This review assesses a

few of the progressing and future bearings of combining next-generation CRISPR-Cas9 quality altering with manufactured science to optimize CAR T-cell and NK cell treatment for future clinical trials toward the foundation of a modern cancer treatment parade.

**Keywords:** CAR T-cell, Cancer, Gene editing, CRISPR, Immunotherapy

# Introduction

Immunotherapy, which uses the patient's immune system to target and kill cancer cells, has become a promising tool for cancer treatment [1].Assenting T cell treatment may be a sort of immunotherapy including the confinement and in vitro development of patient-derived T cells and reinfusion into the cancer patients [2].In this setting, fringe blood T cells are utilized to deliver hereditarily modified-T cells communicating transgenic T cell receptor (TCR) and chimeric antigen receptor T (CAR-T) cells (Figure A) [3].CAR-T cell, a living medicate, has been examined for more than two decades. Aggregate investigate information have illustrated the momentous victory of CAR-T cells in a few hematologic malignancies and strong tumors. Within the starting, CAR T-based treatment has been expectation utilized against hematologic malignancies,especially for patients with B-cell intense lymphoblastic leukemia (B-ALL) [4].Subsequently, the Joined together States Food and Drug Administration of the United States (FDA) affirmed five CAR-T items. (I) Idecabtagene vicleucel (Abecma) is an autologous B-cell development antigen (BCMA) CAR-T cell plan

ned for patients with backslid or hard-headed (R/R) myeloma [5]. (II) Lisocabtagene maraleucel (Breyanzi) is an autologous CD19 CAR-T cell particular for patients with R/R huge B-cell lymphomas[6].(III)Brexucabtagene autoleucel (Tecartus) is an autologous CD19 CAR-T cell outlined for patients with R/R mantle-cell lymphoma [7].(IV) Tisagenlecleucel (Kymriah) is an autologous CD19 CART cell particular for pediatric and youthful grown-up patients with CD19+ R/R Bcell ALL [8].(V) Axicabtagene ciloleucel (Yescarta) is an autologous CD19 CAR-T cell outlined for patients with headstrong expansive B-cell lymphoma [9].CAR-T cells have several limitations that stop them from performing successfully and efficiently.Despite the tremendous clinical success of CAR-T cell therapy in hematologic malignancies, there are multiple hurdles and barriers that restrict successful therapeutic outcomes. CAR-T cells were found to have a limited persistence, proliferation, and expansion in some individuals, especially patients with chronic lymphocytic leukemia (CLL) [10].Moreover, abandons in natural autologous T cells may avoid the victory of CAR-T cells in patients [11].

In a few cancer sorts (e.g., ALL), the treatment may fall flat in patients analyzed with fast dynamic illness who require an quick treatment with CAR-T cells due to the long-time

autologous CAR-T fabricating handle. Furthermore, the satisfactory number of T cell collections from patients with hematologic threat is now and then difficult and impracticable due to lymphopenia from later or earlier chemotherapy or fundamental infection [12] [13].In the interim, there are other issues related with CAR-T cell treatment, counting antigen elude, destitute trafficking and tumor invasion, low determination, restraint and resistance of T cells, and CAR-T relate clinical toxicities [14].Importantly, obstacles such as cost of treatment, gap between leukapheresis and manufacturing,and specific inclusion and exclusion criteria set by clinical trial restrict patients from getting the treatment [15].Moreover, CAR-T treatment has too been utilized against strong tumors and appeared promising helpful approaches; in any case, up to presently FDA endorsed no CAR-T items for strong tumors. This means that the challenges in strong tumors are much more genuine and require an exhaustive examination. A major jump to the victory of CAR-T cell treatment against strong tumors is tumor microenvironment and the need of tumor-specific antigen [16].By the appearance of genome altering innovation, such as clustered frequently interspaced brief palindromic rehashes (CRISPR)/CRISPR associated protein 9 (Cas9) framework, translation activator-like effector nucleases (TALEN), and zinc finger nucleases (ZFNs), there's an opportunity to address numerous of these preventions postured on CAR-T cell treatment [17].Genome editing altering alludes to the conveyance of an altering apparatus framework in cells of intrigued to adjust their genome through either the substitution of defective qualities or addition of unused qualities to treat illnesses or boost the restorative results[18].CRISPR/Cas9 has outperformed the two other genome altering frameworks within the taking after ways: (a) is simple planning; (b) CRISPR/Cas9 recognizes the DNA location through RNA–DNA interaction; (c) comes about in higher specificity and efficiency; (d) gives a simple way to manipulate multiple target DNA, at the same time (high-yield multiplexing); and (e) may be a budget-friendly innovation [19].In the following sections, we provide an overview of CRISPR / Cas9 technology, the challenges and barriers to CAR-T cell therapy, as well as NK cells reviews and, finally, methods that the CRISPR / Cas9 system can potentially discuss. Improve the success of treatment with CAR-T and NK cells.




**Figure A:** Schematic of the association between T cell and Tumor cell

**NK cell therapy**

Natural killer (NK) cells are major players within the safe framework, rather like T cells [20].One of the key contrasts between these cell sorts is that NK cells are portion of the intrinsic resistant framework, whereas T cells are a component of the versatile resistant framework. NK cells perform resistant reconnaissance, watching the circulation system for anomalous cells such as cancer cells, microbes, or virus-infected cells[21].Not at all like T cells,NK cells are not antigen-specific and they basically recognize 'non-self' cells, controlled by both enacting and inhibitory receptors communicated on their surface. When enacted, NK cells discharge cytotoxic particles that lyse the non-self-cell and slaughter its [22].CRISPR to knock-down CD38 in essential NK cell treatment is great at slaughtering cancer cells and does not cause GvHD, which may be a common side impact of other allogeneic resistant cell transplants like CAR-T [23]. In any case, there are a few key issues that have anticipated their broad utilize. This incorporates issues with the ex vivo extension of NK cells for clinical utilize, their moderately brief life expectancy and tirelessness in vivo, and a constrained capacity to invade strong tumors. A few sorts of cancer moreover oversee to create transformations that offer assistance them avoid NK cells [24].Comparative to the later advance in CAR-T cell treatments, CRISPR can be utilized to

upgrade NK cell treatments. For case, like T cells, NKs can too be altered to precise a CAR (CAR-NK). Alongside their intrinsic non-self acknowledgment, the expansion of a CAR implies they can work both particularly and non-specifically, reducing the probability that cancer cells will avoid treatment. CRISPR can too be utilized to make alters that increment the life expectancy of these regularly short-lived cells or to improve their cancer-targeting capacity [25].expression of these oncogenes is particular to cancer cells. Thumping out these qualities through CRISPR-Cas9 is an engaging helpful target since it'll anticipate cancer development [26]. Later cases incorporate a lipid nanoparticle (LNP)-based conveyance approach to disturb the overexpressed PLK1 quality, and a lentivirus conveyance methodology to target numerous cancer-specific indels [27].

## Hereditary reconstructing procedures in NK cell immunotherapy

As examined over, different pathways are ensnared in NK cell anti-tumour insusceptibility [28].In arrange to completely misuse the anti-tumour potential of NK cell immunotherapy, we might have to be at the same time upgrade a few, whereas stifling other, pathways [29].To this conclusion, the multiplex capability of the CRISPR/Cas9 framework impeccably fits this prerequisite.CRISPR/Cas9 offers the ease of site-specific integration of quality of intrigued (with benefactor quality through homology-directed repair pathway), whereas concurrently erasing numerous qualities of intrigued [30].The taking after areas will center on existing and potential gene-editing procedures, where CRISPR/Cas9-based hereditary adjustment is pertinent, to progress NK cell tumor observation by upgrading tumor acknowledgment, enactment, penetration and perseverance, and by antagonizing inhibitory pathways.

## The principle of gene transfer of CRISPR / Cas9 system to T cells

The delivery of CRISPR/Cas9 to edit the genome of interest is defined into three distinct strategies. The primary approach is to utilize plasmid DNA encoding the Cas9 protein and sgRNA from the same vector [31].The moment arranges is to convey the blend of the Cas9 mRNA and the sgRNA. The final methodology could be a ribonucleoprotein (RNP), the complex of Cas9 protein and sgRNA, which is considered invaluable compared with the two other frameworks[32] .The RNP strategy has less off-target impacts since it does not require the conveyance of remote DNA and the complex of Cas9-gRNA corrupts over time. RNP-based conveyance shows a quick, effective and cost-effective strategy to alter the genome of the target. Another advantage of utilizing RNP is the assortment of strategies that can be utilized to provide the Cas9-gRNA complex, counting electroporation [33].In spite of the fact that the primary procedure of delivery, plasmid-based CRISPRCas9 framework, could be a basic and direct approach, it tends to cause off-target change in essential T cells [34].The plasmid-based system encounters several challenges. Upon the entering of plasmid into the desired nucleus, it undergoes the transcription and translation processes to express the encoded proteins. These

processes require more time to effectively target the gene of interest [35].More imperatively, this organize of conveyance was found to result in an irreversible off-target cleavage location [36].The other negative viewpoint of the plasmid-based approach is its estimate confinement, as numerous current vectors have confinements for large-sized qualities. In addition, transfection of plasmid DNA may actuate the cyclic GMP-AMP synthase and, as a result, leads to have [37].The moment procedure is coordinate conveyance of Cas9 mRNA and sgRNA into the target cells to make a Cas9/sgRNA complex interior the cells. One advantage of this approach is the utilize of mRNAs that can be interpreted within the cytoplasm, therefore requiring intracellular conveyance which is much more helpful instead of conveyance to the core. Moreover, the mRNA interpretation handles decreases required time for genome altering. In expansion, mRNA-based conveyance illustrated a rate of off-target impacts compared to the plasmid DNA technique. In any case, this approach is constrained since mRNA is delicate and may get debased amid the conveyance or planning prepare [38].The final frame of CRISPR/Cas9 conveyance is RNP. This approach dodges the forms of translation and interpretation, and gives the speediest implies of quality altering compared to the two other strategies [39].The delivery of RNP gives multiple advantages, including less off-target effects due to the fast degradation of Cas9 nuclease and no need for codon optimization and promoter selection [40].RNP altering is exceptionally quick, and indels can be measured after 3–24 hours. The Cas9 protein is quickly corrupted from cells inside 24 hours, compared to the plasmid electroporation strategy that holds on about 73 hours [41].There are right now a few nonviral nanovectors utilized for RNP conveyance into the cells in vitro, counting DNA nanoclews (the yarn-like DNA nanoparticles synthesized by rolling circle intensification), cationic lipid nanoparticles and lipoplexes (cationic liposomes, composed of nonviral [manufactured] lipid carriers of DNA), gold-based nanoparticles, and zeolitic imidazole systems [42-43].The CRISPR/Cas9 framework can be utilized either some time recently the era of CAR-T cells or after the generation of CAR-T cells. Right now, the RNP conveyance of CRISPR/Cas9 innovation into the T cells speaks to as a promising approach compared to the other strategies of conveyance. T cells have been focused on by lentiviral and adenoviral vectors for conveyance of CRISPR components. These conveyances appear to be ineffectual due to quality disturbance proficiency, weak site-specificity embed, and arbitrary disturbance of undesirable qualities[44] .The in vivo transfection of CRISPR/Cas9 demonstrate experiences diverse issues, counting disturbance effectiveness, insertional mutagenesis, off-target impacts, harmfulness and immunogenicity [45] .

## CRISPR: A Game-Changer in Cancer Therapeutics

Adoptive cell therapies (ACTs) for the treatment of cancer, like TIL, TCR, CAR-T and NK, are alluring over conventional medications such as chemotherapy and radiotherapy since they are more focused on to cancerous tissue, clearing out solid cells untouched [46].All cell-based

immunotherapies include growing (developing) these safe cells ex vivo and re-infusing them into patients so their body has more resistant cells accessible to assault the cancer. These ACTs can be autologous (disconnected from the persistent) or allogeneic (separated from a solid benefactor) [47].Whereas all ACTs have experienced different obstacles in their interpretation into the clinic, in later a long time CRISPR has advertised modern trust for ACT-based cancer treatment. In this segment, we'll investigate the most sorts of cellular immunotherapies utilized to treat cancer, how CRISPR can be utilized to form them more grounded, more secure, and more promptly accessible, and how CRISPR can target cancer specifically.

## TIL and TCR cell therapies

T cells, frequently called T lymphocytes, envelop a few subsets of cells and are a key component of the versatile resistant framework [48].As their title recommends, tumor-infiltrating lymphocytes (TILs) are resistant cells that can attack tumors in arrange to murder cancer cells [49].Autologous TIL treatment includes extricating TILs from a patient's tumor, growing them in huge numbers ex vivo, and re-infusing them into the persistent so they have more TILs accessible to battle cancer[50] .In spite of the early guarantee of TIL treatment, issues with the confinement and ex vivo development of TILs, in conjunction with their moderately constrained capacity to crush tumors, in the long run driven to this approach being sidelined in favor of T-cell receptor (TCR) treatment[51] .Think of TCR treatment as an update to TIL treatment. TCR treatment employments T cells that are hereditarily adjusted to specific particular TCRs on their surface, making them superior at recognizing cancer cells [52] .TCR treatment appeared guarantee, but like TILs, it experienced some deterrents in its clinical interpretation [53].The need of specificity of TCRs driven to issues with the clinical interpretation of TCR treatment since cancer cells can downregulate the expression of MHC to sidestep location by TCR cells[54].Expression of endogenous TCRs nearby the transgenic TCR within the cells is additionally a key issue, causing competition for signaling components, the arrangement of heterodimers that can cause deadly autoimmunity,and graft-versus-host malady (GvHD) [55].GvHD, a condition where joins of solid safe cells recognize the patient's possess cells and tissues as outside and assault them, could be a major concern in any frame of allogeneic (non-self) cellular immunotherapy and can be deadly [56].Sometime recently the appearance of CRISPR, building T cells was time expending, troublesome, and costly[57].Security concerns related with the utilize of retroviral and lentiviral vectors for altering were too a restricting calculate[58] .Luckily, the later CRISPR transformation has driven to a restoration of both TIL and TCR cell treatments [59].In TILs, CRISPR can be utilized to thump out a quality that represses T cell work called cytokine actuated SH2 (CISH) - disturbance of CISH increments TIL hostility towards tumors [60].Within the case of TCR cells, CRISPR can be used for knock-in of the specified TCR to particular locales within the T cell genome to extend its expression. It can

moreover be utilized to thump out the endogenous TCR quality that can cause GvHD and other unfavorable occasions. Besides, CRISPR can create these alters in exceptionally brief timeframes and without the utilize of viral vectors, expanding understanding security results [61]

CAR-T treatment could be a gene-edited cell therapy, whereby T cells are altered to specific a specific chimeric antigen receptor (CAR) on their surface [62].The CAR is particular to the sort of cancer the quiet has, permitting the T cells to recognize the antigens delivered by the cancer cells and murder them [63].Imperatively, CAR does not depend on the nearness of MHC in arrange to recognize and murder cancer cells [64].CAR-T treatments, both autologous (patient-derived) and allogeneic (sound giver determined), right now have a few major impediments. For autologous CAR-T, this incorporates trouble getting expansive numbers of T cells from patients that are lymphopenic due to other medicines and long timeframes for creating an adequate restorative measurements [65].For allogeneic CAR-T, the solid donor-derived cells can be rejected by the understanding resistant framework, cause harmfulness, or initiate GvHD[66]. Shockingly, a few cancers are able to maintain a strategic distance from pulverization by CAR-T cells by overexpressing certain proteins, like modified cell passing protein 1 (PD-1), on their surface[67] .CRISPR-Cas9 quality altering has expanded the security and viability of CAR-T cell therapies in an assortment of ways[68] .Firstly, CRISPR can be utilized to thump within the CAR in a focused on way - for illustration, to a safe harbor location within the genome - to guarantee adequate, long-term expression of the receptor on the cell surface[69] .Furthermore, CRISPR can thump out certain qualities in CAR-T cells to extend their cancer-killing movement .Thirdly, it can be utilized to form alters that minimize CAR-T cell fatigue and increment their long-term multiplication [70].At long last, CRISPR alters can be utilized to produce all inclusive, ‘off-the-shelf’ CAR-T cells from actuated pluripotent stem cells (iPSCs), invalidating collecting confinements, long hold up times, and harmfulness issues [71] .

## Differences between CAR-T treatment and TCR

The most distinction between CAR-T and TCR treatment is the receptors utilized and their mode of activity. In spite of the fact that they sound comparative, CAR-T and TCR work very differently. TCRs are naturally-occurring or negligibly altered receptors, which rely on major histocompatibility complex (MHC) proteins to work and are therefore non-specific. In differentiate; CARs are manufactured receptors that are designed to recognize particular cancer antigens [72].Unlike TCRs, which can recognize extracellular and intracellular components, CARs can as it were recognize extracellular atoms on cancer cells, meaning the extend of targets of CAR-T treatment is less than TCR. CAR-T cells moreover require more antigens to be show in arrange to be actuated compared to TCR cells. Like other cell therapies, CAR-T cells are inclined to getting to be ‘exhausted’, a state in which their adequacy is reduced [73].

## Current Outlook for CRISPR Cancer Treatment

The field of CRISPR cancer treatment is moving at a quick pace, with parcels of exciting proof-of-concept and pre-clinical ponders being distributed routinely, the comes about of the to begin with clinical trials beginning to stream in, and numerous modern trials starting.In this segment, we'll take a see at the current state of CRISPR cancer inquire about and therapy, counting the sorts of cancer that can be treated, pre-clinical considers and clinical trials, and treatments that have been endorsed by the FDA.

## Hematological cancers versus solid tumors

Hematological (blood) cancers, like leukemia, lymphoma, and numerous myeloma,present exceptionally distinctive treatment challenges compared to strong tumors in organs or delicate tissue, like breast, lung, or brain cancers [74].In common, gene-edited cell treatments for hematological malignancies are as of now more progressed than those for strong tumors [75].Whereas tumors can frequently be treated surgically, blood cancers cannot be expelled surgically since they include harmful cells circulating unreservedly within the body [76].In any case, numerous tumors cannot be surgically expelled, or can as it were be mostly evacuated. In these cases, treatment choices gotten to be more troublesome since of the complex TME and its immunosuppressive impacts [77].CAR-T treatments were initially created to treat blood cancers since it is simpler for T cells to assault openly circulating cancer cells instead of tumors, whereas TILs can be utilized to target strong tumors [78].In all cases, CRISPR is being utilized to improve these treatments, expanding their security and adequacy, and lessening their costs and generation times [79].

## Current preclinical investigate and clinical trials

Current CRISPR cancer inquire about incorporates building TILs to be safe to the molecules that cancer cells express in arrange to switch lymphocytes off, the creation of universal, off-the-shelf CAR T cells, and the altering of NK cells for way better cancer focusing on[80] .For an in-depth see at the diverse ways CRISPR can be utilized for cancer immunotherapy, check out this 2022 review.In a clinical setting, current CRISPR-based trials incorporate medications for non-small-cell lung cancer (NSCLC), esophageal cancer, cervical cancer, metastatic gastrointestinal cancer, T- and B-cell malignancies, multiple myeloma, melanoma, and acute myeloid leukemia (AML), (Important clinical trials related to the CAR-T cell are listed in Table A) [81-82] .Intellia Therapeutics, who was as of now working on CAR-T treatments, reported collaboration with ONK Therapeutics to work on a few diverse CRISPR-edited NK treatments of cancer. The FDA has moreover as of late fast-tracked a CRISPR-edited TCR cell treatment for the treatment of AML from Intellia Therapeutics, NTLA-5001. In a pre-clinical consider, Editas Pharmaceutical has

created iPSC-derived NK cells (iNK), utilizing CRISPR-Cas12a to knock-in qualities that increment NK cell tirelessness and tumor-killing capacity.

**Table (A):** clinical trials based on the CAR-T cell therapy in the context of the tumor immunotherapy registered in ClinicalTrials.gov (May 2022)

| NCT number | Condition | Participant Number | Location | Status |
|---|---|---|---|---|
| NCT04280133 | Hematologic Malignancy | 60 | United States | Recruiting |
| NCT04892433 | CAR-T Cell Therapy | 150 | Italy | Recruiting |
| NCT04657861 | Multiple Myeloma in Relapse<br>Multiple Myeloma, Refractory | 36 | China | Recruiting |
| NCT04658004 | Acute Myeloid Leukemia | 36 | China | Not yet recruiting |
| NCT04670055 | Relapse Multiple Myeloma<br>Refractory Multiple Myeloma | 50 | China | Not yet recruiting |
| NCT04541368 | Relapse Multiple Myeloma | 50 | China | Not yet recruiting |
| NCT04532203 | Acute Lymphoblastic Leukemia<br>Non-Hodgkin's Lymphoma | 72 | China | recruiting |
| NCT04532268 | Acute Lymphoblastic Leukemia<br>Non-hodgkin Lymphoma,B Cell | 72 | China | recruiting |
| NCT04703686 | Lymphoma | 78 | France | Recruiting |
| NCT03758417 | MM | 60 | China | Active, not recruiting |
| NCT03631576 | AML | 20 | China | Recruiting |
| NCT03937544 | B-ALL | 10 | Malaysia | Recruiting |
| NCT03068416 | B cell leukemia/lymphoma | 25 | Sweden | Active, not recruiting |
| NCT04723901 | B-ALL | 20 | China | Recruiting |
| NCT04723914 | B cell lymphoma | 20 | China | Recruiting |
| NCT03684889 | Leukemia or lymphoma | 16 | USA | Active, not recruiting |
| NCT04697940 | NHL | 30 | China | Recruiting |
| NCT04581473 | Gastric and pancreatic cancers | 102 | China | Recruiting |
| NCT03525782 | NSCLC | 60 | China | Recruiting |
| NCT04010877 | AML | 10 | China | Recruiting |
| NCT04499339 | MM | 38 | Germany | Recruiting |
| NCT04429438 | B cell lymphoma | 11 | China | Recruiting |
| NCT04404660 | B-ALL | 185 | Germany | Recruiting |
| NCT03916679 | Ovarian cancer | 20 | China | Recruiting |
| NCT04097301 | AML and MM | 58 | Italy | Recruiting |
| NCT03356782 | Sarcoma | 20 | China | Recruiting |
| NCT02132624 | B-ALL | 15 | Sweden | Completed |
| NCT03767751 | MM | 80 | China | Recruiting |
| NCT03289455 | B-All | 23 | UK | Completed |
| NCT03288493 | MM | 220 | USA | Recruiting |
| NCT04718883 | MCL | 59 | China | Recruiting |
| NCT04010877 | AML | 10 | China | Recruiting |
| NCT04148430 | B-ALL and B-NHL | 90 | USA | Recruiting |
| NCT04484012 | MCL | 36 | USA | Recruiting |
| NCT04268706 | HL | 94 | USA | Recruiting |
| NCT03373071 | ALL and NHL | 32 | Italy | Recruiting |
| NCT03373097 | Neuroblastoma | 42 | Italy | Recruiting |

| | | | | |
|---|---|---|---|---|
| NCT04653649 | HL | 30 | Spain | Recruiting |
| NCT04429451 | Solid tumors | 100 | China | Recruiting |
| NCT00924326 | B cell lymphoma | 43 | USA | Active, not recruiting |
| NCT04206943 | ALL and NHL | 24 | Turkey | Recruiting |
| NCT04257578 | B cell lymphoma | 20 | USA | Recruiting |
| NCT01475058 | B cell lymphoma | 1 | USA | Completed |
| NCT01583686 | Solid tumors | 15 | USA | Terminated |
| NCT01218867 | Melanoma and renal cancers | 24 | USA | Terminated |
| NCT04553393 | NHL | 80 | China | Recruiting |
| NCT02744287 | Pancreatic and prostate cancer | 151 | USA | Recruiting |
| NCT03173417 | Leukemia | 177 | China | Completed |
| NCT04340167 | ALL | 100 | China | Recruiting |
| NCT03097770 | B cell leukemia or lymphoma | 100 | China | Completed |
| NCT03706326 | Esophageal cancer | 20 | China | Recruiting |
| NCT04186520 | NHL MCL | 32 | USA | Recruiting |
| NCT04648475 | B cell leukemia/ lymphoma | 40 | China | Recruiting |
| NCT04571138 | B cell leukemia/ lymphoma | 42 | USA | Recruiting |
| NCT02028455 | Acute leukemia | 167 | USA | Active, not recruiting |
| NCT03467256 | B-ALL | 18 | Russian | Active, not recruiting |
| NCT04544592 | B-ALL and B-NHL | 50 | USA | Recruiting |
| NCT03765177 | ALL and NHL | 60 | Canada | Recruiting |
| NCT03448978 | MM | 30 | USA | Recruiting |
| NCT03573700 | ALL | 35 | USA | Recruiting |
| NCT02744287 | Pancreatic and prostate cancer | 151 | USA | Recruiting |
| NCT04029038 | B cell leukemia/ lymphoma | 30 | USA | Not yet recruiting |
| NCT04649983 | B cell leukemia/ lymphoma | 40 | China | Recruiting |
| NCT04846439 | Acute leukemia | 20 | China | Recruiting |
| NCT01454596 | Brain tumors | 18 | USA | Completed |
| NCT04206943 | ALL and NHL | 24 | Turkey | Recruiting |
| NCT03125577 | B cell malignancies | 100 | China | Recruiting |
| NCT02535364 | B-ALL | 82 | USA | Terminated |
| NCT02445248 | DLBCL | 115 | USA | Active, not recruiting |
| NCT04836507 | Adult large B cell lymphoma | 91 | South Korea | Recruiting |
| NCT03954106 | DLBCL | 25 | USA | Terminated |
| NCT03941626 | Solid tumors | 50 | China | Recruiting |
| NCT02772198 | B- ALL and B-NHL | 300 | Israel | Recruiting |
| NCT04787263 | ALL, DLBCL and PML | 32 | Italy | Recruiting |
| NCT02992834 | B cell lymphoma | 10 | China | Not yet recruiting |
| NCT03938987 | NHL and ALL | 63 | Canada | Recruiting |
| NCT03971799 | AML | 34 | USA | Recruiting |
| NCT03676504 | ALL, NHL, CLL, DLBCL, FL MCL | 48 | Germany | Recruiting |
| NCT04077866 | Glioblastoma | 40 | China | Recruiting |
| NCT03076437 | AML and CLL | 28 | China | Completed |
| NCT04133636 | MM | 120 | USA | Recruiting |
| NCT02650999 | DLBCL, FL and MCL | 12 | USA | Active, not recruiting |
| NCT03097770 | B cell malignancy | 100 | China | Completed |
| NCT04599556 | T-ALL, T-NHL and AML | 108 | China | Recruiting |
| NCT03706326 | Esophageal cancer | 20 | China | Recruiting |
| NCT04186520 | NHL and MCL | 32 | USA | Recruiting |
| NCT04571138 | Leukemia/lymphoma | 42 | USA | Recruiting |
| NCT03356795 | Cervical cancer | 20 | China | Recruiting |
| NCT02028455 | Acute leukemia | 167 | USA | Active, not recruiting |
| NCT03467256 | B-ALL | 18 | Russian | Active, not recruiting |
| NCT04544592 | B-ALL and B-NHL | 50 | USA | Recruiting |

| | | | | |
|---|---|---|---|---|
| NCT03765177 | ALL and NHL | 60 | Canada | Recruiting |
| NCT02690545 | HL and NHL | 40 | USA | Recruiting |
| NCT03448978 | MM | 30 | USA | Recruiting |
| NCT04083495 | T cell lymphoma | 20 | USA | Recruiting |
| NCT02414269 | Solid tumors | 179 | USA | Recruiting |
| NCT03483103 | B- NHL | 61 | USA | Active, not recruiting |

https://clinicaltrials.gov/

## Long-standing Time of CRISPR Cancer Therapeutics

Scientists are confident that the utilize of both gene-edited cell treatments and in vivo CRISPR quality altering will empower the treatment of numerous sorts of cancer. However, we're as it was fair starting to scratch the surface of what CRISPR is able to do in this region of investigate. Later adjustments of CRISPR innovation, counting recently found Cas nucleases, are uncovering indeed more roads for cancer therapeutics. For illustration, the revelation of compact sort I-C Cascade-Cas3 frameworks offers the plausibility of making large-scale cancellations in tumor survival genes in arrange to slaughter cancer, since Cas3 shreds large sections of DNA instead of making double-stranded breaks. Other adjustments of CRISPR frameworks which will demonstrate restoratively significant to cancer treatment incorporate CRISPR-based epigenome altering (eGE), which can be utilized to switch on tumor silencer qualities or switch off oncogenes, or something else change epigenetic changes related with cancer.With a combination of current and developing CRISPR innovations for the treatment of cancer, we're likely to see a fast increment in pre-clinical considers and clinical trials over the another few a long time. As the comes about of the progressing trials proceed to appear guarantee, and CRISPR frameworks are encourage refined in terms of security and viability, the advancement of cancer cures at last appears inside reach.

# References


1-Jitwadee Inthagard; Joanne Edwards ; Antonia K. Roseweir . Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers . *Clin Sci (Lond)* (2019) 133 (2): 181–193.

2- Robin Parihar; Charlotte Rivas; Mai Huynh; Bilal Omer; Natalia Lapteva; Leonid S. Metelitsa; Stephen M. Gottschalk; Cliona M. Rooney. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res (2019) 7 (3): 363–375.

3- Venugopal Gudipati, Julian Rydzek, Iago Doel-Perez, Vasco Dos Reis Gonçalves, Lydia Scharf, Sebastian Königsberger, Elisabeth Lobner, Renate Kunert, Hermann Einsele, Hannes Stockinger, Michael Hudecek & Johannes B. Huppa. Inefficient CAR-proximal signaling blunts antigen sensitivity. *Nature Immunology* volume 21, pages848–856 (2020).

4- Rimjhim Mohanty ,Chitran Roy Chowdhury , Solomon Arega ,Prakriti Sen , Pooja Ganguly ,Niladri Ganguly. CAR T cell therapy: A new era for cancer treatment (Review). OncologyReports 2183-2195.

5- Munshi, N. C., Anderson, L. D., Jr., Shah, N., Madduri, D., Berdeja, J.,Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H.,Weisel, K., Rambaldi, A., Reece, D., San-Miguel, J. (2021).Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384(8), 705–716.

6- Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M.,Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C.,Sehgal, A., Solomon, S. R., Ghosh, N., Albertson, T. M., Garcia, J.,Kostic, A., Mallaney, M., Ogasawara, K., Newhall, K., Siddiqi, T.(2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet, 396(10254), 839–852.

7- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W.,McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M. J.,Milpied, N., Fung, H., Topp, M. S., Houot, R., Reagan, P. M. (2020).KTE-X19 CAR-T cells therapy in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 382(14), 1331–1342.

8- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M.,Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E.,Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K.,Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C.Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine,378(5), 439–448.

9- Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y.,Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., … Go, W. Y. (2017).Axicabtagene ciloleucel CAR-T cells therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26),2531–2544.

10- Sarah Charrot, and Simon Hallam. CAR-T Cells: Future Perspectives. Hemasphere.

11- Jean Lemoine, Marco Ruella & Roch Houot. Born to survive: how cancer cells resist CAR T cell therapy. Journal of Hematology & Oncology volume 14, Article number: 199 (2021)

12- Sadeqi Nezhad, M., Abdollahpour-Alitappeh, M., Rezaei, B., Yazdanifar, M., & Seifalian, A. M. (2021). Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products. Pharmaceutical Research,38, 931–945.

13-Singh, N., Perazzelli, J., Grupp, S. A., & Barrett, D. M. (2016). Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Science Translational Medicine, 8(320), 320–323.

14-Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11(4), 69.

15- Nico Gagelmann, Kristoffer Riecken, Christine Wolschke, Carolina Berger, Francis A. Ayuk, Boris Fehse & Nicolaus Kröger . Multiple myeloma gammopathies Development of CAR-T cell therapies for multiple myeloma. Leukemia volume 34, pages2317–2332 (2020)

16- Faroogh Marofi, Roza Motavalli, Vladimir A. Safonov, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Markov Alexander, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Mostafa Jarahian, Sepideh Izadi, Ali Hassanzadeh, Naghmeh Shirafkan, Safa Tahmasebi & Farhad Motavalli Khiavi . CAR T cells in solid tumors: challenges and opportunities. Stem Cell Research & Therapy volume 12, Article number: 81 (2021)

17- Juanjuan Zhao, Quande Lin, Yongping Song & Delong Liu . Universal CARs, universal T cells, and universal CAR T cells. Journal of Hematology & Oncology volume 11, Article number: 132 (2018)

18- Jennifer A. Doudna . The promise and challenge of therapeutic genome editing. Nature volume 578, pages229–236 (2020)

19- Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020).Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects. Signal Transduction and Targeted Therapy, 5(1), 1.

20- Kristina S. Burrack,1 Geoffrey T. Hart,2 and Sara E. Hamilton. Contributions of natural killer cells to the immune response against Plasmodium. Malar J. 2019; 18: 321.

21-Preeti Sharma,corresponding author Pradeep Kumar and Rachna Sharma. Natural Killer Cells - Their Role in Tumour Immunosurveillance. J Clin Diagn Res .Published online 2017 Aug 1.

22- Faroogh Marofi, Heshu Sulaiman Rahman, Lakshmi Thangavelu, Aleksey Dorofeev, Favian Bayas-Morejón, Naghmeh Shirafkan, Navid Shomali, Max Stanley Chartrand, Mostafa Jarahian, Ghasem Vahedi, Rebar N. Mohammed, Somayeh Shahrokh, Morteza Akbari & Farhad Motavalli Khiavi . Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Research & Therapy volume 12, Article number: 200 (2021)

23- Luyao Wang, 1 , 2 Yurong Chen, 1 , 2 Xinrui Liu, 3 Ziyi Li, 1 , 2 and Xiangpeng Daicorresponding author . The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems. Front Oncol. 2021; 11: 704999.Published online 2022 Jan 17.

24- Philippa R. Kennedy, Martin Felices & Jeffrey S. Miller. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer. Stem Cell Research & Therapy volume 13, Article number: 165 (2022)

25-FatemehVahidian,Leila MohamedKhosroshahi, Moloud Akbarzadeh , AliJahanban Esfahlan, Amir Baghbanzadeh, Mohammad Ali-Hassanzadeh, Elham Safarzadehi. The tricks for fighting against cancer using CAR NK cells: A review. Molecular and Cellular Probes. Volume 63, June 2022, 101817

26- Katarzyna Balon, Adam Sheriff, Joanna Jacków,and Łukasz Łaczmański.Hidekazu Suzuki. Targeting Cancer with CRISPR/Cas9-Based Therapy. Int J Mol Sci. 2022 Jan; 23(1): 573.

27-JingyueYana, Diana D.Kanga, GillianTurnbulla, YizhouDongab. Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer. Advanced Drug Delivery Reviews. Volume 180, January 2022, 114042

28- Tobias Bald, Matthew F. Krummel, Mark J. Smyth, and Kevin C. Barry. The NK cell-cancer cycle - advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020 Aug; 21(8): 835–847.

29-WanzeZhangaZhenghuaZhaoaFanLiabcde. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Molecular Immunology. Volume 144, April 2022, Pages 58-70

30- Hyeon-Ki Jang, Beomjong Song, Gue-Ho Hwang & Sangsu Bae . Current trends in gene recovery mediated by the CRISPR-Cas system. Experimental & Molecular Medicine volume 52, pages1016–1027 (2020)

31- Lino, Jason C. Harper, James P. Carney, and Jerilyn A. Timlin. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018; 25(1): 1234–1257.

32- Pin Lyu, Parisa Javidi-Parsijani, Anthony Atala and Baisong Lu. Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient 'hit-and-run' genome editing. Nucleic Acids Res. 2019 Sep 26; 47(17): e99.

33- Song Zhang, Jiangtao Shen, Dali Li, and Yiyun Cheng. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. Theranostics. 2021; 11(2): 614–648.

34- Kornete, M., Marone, R., & Jeker, L. T. (2018). Highly efficient and versatile plasmid-based gene editing in primary T cells. The Journal of Immunology, 200(7), 2489–2501.

35- Fujihara, Y., & Ikawa, M. (2014). CRISPR/Cas9-based genome editing in mice by single plasmid injection. Methods in Enzymology, 546,319–336.

36- Muhammad Naeem,1 Saman Majeed,2 Mubasher Zahir Hoque,1 and Irshad Ahmad1. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing. Cells. 2020 Jul; 9(7): 1608.

37- Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019). Delivery of CRISPR/Cas9 for therapeutic genome editing. The Journal of Gene Medicine, 21(7), e3107.

38- Chang Liu, Li Zhang, Hao Liu, and Kun Cheng. Delivery Strategies of the CRISPR-Cas9 Gene-Editing System for Therapeutic Applications. J Control Release. 2017 Nov 28; 266: 17–26.

39- Bon Ham Yip. Recent Advances in CRISPR/Cas9 Delivery Strategies. Biomolecules. 2020 Jun; 10(6): 839.

40- Yi Lin a, Ernst Wagner ORCID logo*a and Ulrich Lächelt . Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP. Biomater. Sci., 2022, 10, 1166-1192.

41- Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Research, 24(6), 1012–1019.

42- Wei, T., Cheng, Q., Min, Y.-L., Olson, E. N., & Siegwart, D. J. (2020).Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nature Communications, 11(1), 3232.

43-Brittany E. Givens,1,2,‡ Youssef W. Naguib,1,3,‡ Sean M. Geary,1 Eric J. Devor,4 and Aliasger K. Salem. Nanoparticle based delivery of CRISPR/Cas9 genome editing therapeutics. AAPS J. 2018 Oct 10; 20(6): 108.

44-Alexander Dimitri,1,2,3 Friederike Herbst,2,3,4 and Joseph A. Fraiettacorresponding author. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022; 21: 78.

45- Ehsan Razeghian, Mahyuddin K. M. Nasution, Heshu Sulaiman Rahman, Zhanna R. Gardanova, Walid Kamal Abdelbasset, Surendar Aravindhan, Dmitry O. Bokov, Wanich Suksatan, Pooria Nakhaei, Siavash Shariatzadeh, Faroogh Marofi, Mahboubeh Yazdanifar, Somayeh Shamlou, Roza Motavalli & Farhad Motavalli Khiavi . A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.Stem Cell Research & Therapy volume 12, Article number: 428 (2021)

46-Aleksei Titov , Ekaterina Zmievskaya , Irina Ganeeva , Aygul Valiullina , Alexey Petukhov , Aygul Rakhmatullina , Regina Miftakhova , Michael Fainshtein , Albert Rizvanov , Emil Bulatov . Adoptive Immunotherapy beyond CAR T-Cells. Review Cancers (Basel)

47-Jeffrey Koury,corresponding author Mariana Lucero, Caleb Cato, Lawrence Chang, Joseph Geiger, Denise Henry, Jennifer Hernandez, Fion Hung, Preet Kaur, Garrett Teskey, and Andrew Tran. Immunotherapies: Exploiting the Immune System for Cancer Treatment. J Immunol Res.

48-Brahma V. Kumar, Thomas Connors, and Donna L. Farber.Human T cell development, localization, and function throughout life. Immunity. Volume 48, Issue 2, 20 February 2018, Pages 202-213

49-Anaïs Jiménez-Reinoso, Daniel Nehme-Álvarez, Carmen Domínguez-Alonso, and Luis Álvarez-Vallina. Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential. Front. Oncol.

50-Paul Mayor, Kristen Starbuck and Emese Zsiros. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol. Volume 150, Issue 2, August 2018, Pages 361-369

51-Richard Wu,1,2 Marie-Andree Forget,1 Jessica Chacon,1,2 Chantale Bernatchez,1 Cara Haymaker,1 Jie Qing Chen,1 Patrick Hwu,1,2 and Laszlo Radvanyi. Adoptive T-cell Therapy Using Autologous Tumor-infiltrating Lymphocytes for Metastatic Melanoma: Current Status and Future Outlook. Cancer J. 2012;18(2):160-75.

52-Lijun Zhao and Yu J. Cao. Engineered T cell Therapy for Cancer in the Clinic. Front. Immunol .

53-Matteo Morotti, Ashwag Albukhari, Abdulkhaliq Alsaadi, Mara Artibani, James D. Brenton, Stuart M. Curbishley, Tao Dong, Michael L. Dustin, Zhiyuan Hu, Nicholas McGranahan, Martin L. Miller, Laura Santana-Gonzalez, Leonard W. Seymour, Tingyan Shi, Peter Van Loo, Christopher Yau, Helen White, Nina Wietek, David N. Church, David C. Wedge & Ahmed A. Ahmed . Promises and challenges of adoptive T-cell therapies for solid tumours.British Journal of Cancer volume 124, pages1759–1776 (2021)

54-Qinghua He,1 Xianhan Jiang,2 Xinke Zhou,corresponding author1,2 and Jinsheng Wengcorresponding author. Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 12, Article number: 139 (2019)

55- Chandran, Smita S., and Christopher A. Klebanoff. "T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance." Immunological reviews 290.1 (2019): 127-147.

56- Sung, Anthony D., and Nelson J. Chao. "Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment." Stem cells translational medicine 2.1 (2013): 25-32.

57- You, Liting, et al. "Advancements and obstacles of CRISPR-Cas9 technology in translational research." Molecular Therapy-Methods & Clinical Development 13 (2019): 359-370.

58- Marcucci, Katherine T., et al. "Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients." Molecular therapy 26.1 (2018): 269-279.

59- Ghaffari, Sasan, Nastaran Khalili, and Nima Rezaei. "CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy." Journal of Experimental & Clinical Cancer Research 40.1 (2021): 1-18.

60- Fix, Samantha M., Amir A. Jazaeri, and Patrick Hwu. "Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for CancerCRISPR-Enhanced Adoptive Cell Therapies for Cancer." Cancer discovery 11.3 (2021): 560-574.

61- Ghaffari, Sasan, Nastaran Khalili, and Nima Rezaei. "CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy." Journal of Experimental & Clinical Cancer Research 40.1 (2021): 1-18.

62- Dimitri, Alexander, Friederike Herbst, and Joseph A. Fraietta. "Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing." Molecular Cancer 21.1 (2022): 1-13.

63- Benmebarek, Mohamed-Reda, et al. "Killing mechanisms of chimeric antigen receptor (CAR) T cells." International journal of molecular sciences 20.6 (2019): 1283.

64- Dhatchinamoorthy, Karthik, Jeff D. Colbert, and Kenneth L. Rock. "Cancer immune evasion through loss of MHC class I antigen presentation." Frontiers in immunology 12 (2021): 636568.

65- Graham, Allogeneic CAR-T. "Cells: More than Ease of Access." 155.

66- Wagner, Dimitrios L., et al. "Immunogenicity of CAR T cells in cancer therapy." Nature Reviews Clinical Oncology 18.6 (2021): 379-393.

67- Alex D. Waldman, Jill M. Fritz & Michael J. Lenardo .A guide to cancer immunotherapy: from T cell basic science to clinical practice.Nature Reviews Immunology volume 20, pages651–668 (2020).
68- Salas-Mckee, January, et al. "CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy." Human vaccines & immunotherapeutics (2019).

69- Schober, Kilian, Thomas R. Müller, and Dirk H. Busch. "Orthotopic T-Cell Receptor Replacement—An “Enabler” for TCR-Based Therapies." Cells 9.6 (2020): 1367.

70- Azangou-Khyavy, Mohammadreza, et al. "CRISPR/Cas: From tumor gene editing to T cell-based immunotherapy of cancer." Frontiers in Immunology 11 (2020): 2062.

71- Rezalotfi, Alaleh, et al. "Challenges of CRISPR-based gene editing in primary T cells." International Journal of Molecular Sciences 23.3 (2022): 1689.

72- Wachsmann, Tassilo LA, et al. "Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure." Oncoimmunology 11.1 (2022): 2033528.

73- Salter, Alexander I., et al. "Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function." Science signaling 14.697 (2021): eabe2606.

74- Kievit, Forrest M., and Miqin Zhang. "Cancer therapy: cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers (adv. Mater. 36/2011)." Advanced Materials 23.36 (2011): H209-H209.

75- Chung, Hyunmin, Haiyoung Jung, and Ji-Yoon Noh. "Emerging approaches for solid tumor treatment using CAR-T cell therapy." International journal of molecular sciences 22.22 (2021): 12126.

76- Tohme, Samer, Richard L. Simmons, and Allan Tsung. "Surgery for cancer: a trigger for metastases." Cancer research 77.7 (2017): 1548-1552.

77- Alieva, Maria, Jacco van Rheenen, and Marike LD Broekman. "Potential impact of invasive surgical procedures on primary tumor growth and metastasis." Clinical & Experimental Metastasis 35.4 (2018): 319-331.

78- Martinez, Marina, and Edmund Kyung Moon. "CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment." Frontiers in immunology 10 (2019): 128.

79- Uddin, Fathema, Charles M. Rudin, and Triparna Sen. "CRISPR gene therapy: applications, limitations, and implications for the future." Frontiers in oncology 10 (2020): 1387.

80- Morgan, Michael A., et al. "Use of cell and genome modification technologies to generate improved “off-the-shelf” CAR T and CAR NK cells." Frontiers in immunology 11 (2020): 1965.

81- Mirza, Zeenat, and Sajjad Karim. "Advancements in CRISPR/Cas9 technology—focusing on cancer therapeutics and beyond." Seminars in Cell & Developmental Biology. Vol. 96. Academic Press, 2019.

82- Ramezankhani, Roya, et al. "Gene editing technology for improving life quality: A dream coming true?." Clinical Genetics 99.1 (2021): 67-83.